AdAlta Limited

AdAlta Limited is a clinical-stage biotechnology company specializing in the development of next-generation cell and protein therapeutics through its proprietary i-body platform. This innovative technology produces human single-domain antibody-like molecules, mimicking shark-derived antigen-binding domains to target challenging proteins such as G-protein coupled receptors (GPCRs) involved in fibrosis, inflammation, cancer, and infectious diseases. The company's lead asset, AD-214, targets fibrotic conditions like idiopathic pulmonary fibrosis, kidney fibrosis, and age-related macular degeneration, addressing high unmet needs where current treatments fall short; it has advanced to Phase II trials and seeks external partners for further development. AdAlta employs an 'East to West' strategy, in-licensing differentiated T-cell therapies from Asia for solid cancers—representing 90% of cancer cases—and leveraging Australia's manufacturing and clinical expertise for US FDA-regulated Phase I studies, enabling on-licensing to global biopharma firms. Additional programs include WD-34, a novel protein inhibiting all malaria strains and related parasites for potential traveler protection, and collaborations like those with GE Healthcare for immuno-oncology imaging and Carina Biotech for CAR-T therapies. Headquartered in Melbourne, Australia, and listed publicly since 2016, AdAlta pursues a capital-efficient, scalable model to capture growth in the expanding cellular immunotherapy market.